Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: Results of a prospective, multicenter, open-label study

Thrombosis Research

Volumn 130, Issue SUPPL. 2, 2012, Pages

  Nugent, Diane ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Congenital; Corifact ; Efficacy; Factor XIII deficiency; Fibrogammin P; FXIII concentrates; Pharmacokinetics; Plasma derived; Prophylaxis; Safety

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; CORIFACT; FRESH FROZEN PLASMA; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE INJURY; APPENDICITIS; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIP INJURY; HUMAN; INFANT; LACERATION; MALE; MULTICENTER STUDY; PATIENT MONITORING; PHARMACOKINETICS; PHYSICAL EXAMINATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SCHOOL CHILD; THORAX INJURY; THORAX PAIN; TREATMENT DURATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FACTOR XIII DEFICIENCY; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; INFANT; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84874628642     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70005-7     Document Type: Conference Paper

References (13)

1. L Muszbek, Z Bereczky, Z Bagoly, I Komáromi, É Katona Factor XIII: a coagulation factor with multiple plasmatic and cellular functions Physiol Rev 91 2011 931 972
2. L Hsieh, D Nugent Factor XIII deficiency Haemophilia 14 2008 1190 1200
3. J Lusher, SW Pipe, S Alexander, D Nugent Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study Haemophilia 16 2010 316 321
4. R Anwar, KJ Miloszewski Factor XIII deficiency Br J Haematol 107 1999 468 484
5. DJ Nugent Prophylaxis in rare coagulation disorders-factor XIII deficiency Thromb Res 118 Suppl 1 2006 S23 S28
6. R Egbring, A Kröniger, R Seitz Factor XIII deficiency: pathogenic mechanisms and clinical significance Semin Thromb Hemost 22 1996 419 425 (Pubitemid 27050712)
7. PH Bolton-Maggs, DJ Perry, EA Chalmers, LA Parapia, JT Wilde, MD Williams et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation Haemophilia 10 2004 593 628 (Pubitemid 39317772)
8. National Hemophilia Foundation MASAC recommendation 210. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders Available at: http://www.hemophilia.org/NHFWeb/ MainPgs/MainNHF.aspx?menuid=57&contentid=693 last accessed August 13, 2012.
9. U.S. Food and Drug Administration Transfusion-related acute lung injury [advisory letter]. October 19, 2001 Available at: http://www.fda.gov/ BiologicsBloodVaccines/SafetyAvailability/ucm105850.htm last accessed August 13, 2012.
10. M Dreyfus, D Barrois, JY Borg, S Claeyssens, MF Torchet, B Arnuti et al. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study J Thromb Haemost 9 2011 1264 1266
11. A Inbal, J Oldenburg, M Carcao, A Rosholm, R Tehranchi, D Nugent Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency Blood 119 2012 5111 5117
12. Corifact™ Full Prescribing Information CSL Behring GmbH, Marburg, Germany. Revision dated February 2011 Available at: http://www.cslbehring-us. com/docs/495/941/Corifact-Prescribing-Information.pdf last accessed August 13, 2012.
13. U.S. Food and Drug Administration Corifact™ Final Clinical Review 2010 Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/UCM247120.pdf last accessed August 13, 2012.